Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Yale researchers have created a DNA‑based nanodevice that can tug on individual proteins with piconewton precision. The U‑shaped frame clamps a protein via DNA handles that fold to apply controlled tension. Using talin as a test case, the device reproduced known vinculin binding and uncovered a new force‑dependent interaction with filamin. The platform is designed to be reconfigurable for a wide range of linear proteins and potentially for more complex structures.
Researchers have engineered hybrid cryomicroneedle patches (pG/DL@npDC‑cryoMNs) that embed a neuroprotective dendritic cell vaccine within a methacrylated decellularized lymph‑node matrix and porous GelMA hydrogel. The device rapidly releases viable npDCs, triggers a strong CD4⁺ T‑cell response, and forms a non‑typical...
Fresenius Kabi and Phlow Corp. have launched the United States’ first end‑to‑end domestic manufacturing collaboration for epinephrine injection, pairing Phlow’s new API production facility in Virginia with Fresenius Kabi’s existing formulation and fill sites. The partnership includes an FDA‑filed Drug...
The FDA launched an aggressive crackdown on pharmaceutical advertising last fall, issuing thousands of warning letters to drugmakers over misleading consumer ads. Despite the heightened scrutiny, the industry continued to pour roughly $2 billion into promotional campaigns, shifting spend toward digital...
Targeted protein degraders that eliminate the transcription factors WIZ and ZBTB7A are shown to raise fetal hemoglobin (HbF) levels, offering a disease-modifying strategy for sickle cell disease and β‑thalassemia. Novartis disclosed a series of CRBN‑based glue degraders, culminating in the...
Hims & Hers shares plunged up to 27% after the FDA announced it will take decisive steps to restrict non‑FDA‑approved compounded GLP‑1 active pharmaceutical ingredients. The regulator’s move coincides with a lawsuit from Novo Nordisk seeking to block Hims &...
Researchers at Chiba University have experimentally quantified how poloxamer 407 (P407) micelles interact in phosphate‑buffered saline, a physiologically relevant medium. Using small‑angle X‑ray scattering and dynamic light scattering, they derived the pair interaction potential and observed that micelles become more regularly...
South Korean biotech Galux secured $29 million in a Series B round to accelerate its AI‑driven research platform that designs novel protein therapeutics. The funding, led by regional venture partners, will expand Galux’s computational pipeline and scale up pre‑clinical collaborations. In parallel,...
Researchers have unveiled a hand‑warm, DNA‑based lateral‑flow strip that detects feline parvovirus (FPV) and canine parvovirus (CPV) with 100 % sensitivity in clinic samples. The assay amplifies the VP2 gene in about 35 minutes, then displays a red line on a...
$NVO exec: "Anybody who is infringing our patents should be very, very much on notice that we take that seriously, and that we will enforce our patents.…If anybody out there thinks we will not, this should be a wake-up...
🧵 So You Want to Be a Computational Biologist? 1/ Bioinformatics is more than just coding. It’s data analysis, modeling, pipelines, and detective work. Here’s what you must know. 👇 https://t.co/oJxsWkBYzP
Researchers at Eli Lilly and Monash University have advanced a multivalent fragment, muvalaplin (LY3473329), to target the Kringle IV‑8 domain of apolipoprotein(a). The trimeric molecule binds three copies of KIV8, achieving picomolar inhibition of Lp(a) assembly in vitro and lowering...
Roche announced that its Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib achieved non‑inferior efficacy to the company’s blockbuster Ocrevus in a Phase 3 trial for primary progressive multiple sclerosis (PPMS). The oral agent lowered the risk of confirmed disability progression by 12%...
Briya, a health‑AI firm, announced Brian Creighton as Executive Director of Client Strategy to accelerate its U.S. expansion. Creighton brings more than two decades of medical imaging and AI sales experience, most recently as VP of Sales at Merative. He...
Drug Hunter has launched a Module 1 Quiz to evaluate learners’ grasp of introductory drug‑discovery concepts. The quiz spans all sections of the first module and is accessible through the platform’s subscription model. Users can take the assessment after reviewing the...
The breast‑cancer pipeline is heating up as several late‑stage candidates demonstrate significant efficacy across sub‑types. Roche’s oral SERD giredestrant cut invasive disease recurrence by 30% in early‑stage ER‑positive patients, while AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor reduced progression risk...
Biogen expects Phase 2 readout for its tau‑targeting antisense oligonucleotide BIIB080 in the second or third quarter of 2026. The CELIA trial evaluates three dose levels through week 76 and uses cognition as the primary endpoint. A positive signal could lift Biogen’s...
Takeda Pharmaceutical announced a multi‑year research agreement with San Diego biotech Iambic to develop AI‑driven small‑molecule drug candidates. The collaboration merges Takeda’s therapeutic expertise with Iambic’s generative AI platform to accelerate hit identification and lead optimization. Joint R&D labs, data...
Japan’s largest drugmaker Takeda has signed a multiyear agreement with AI specialist Iambic Therapeutics, potentially worth more than $1.7 billion. The partnership grants Takeda access to Iambic’s AI‑driven drug discovery platform and a protein‑receptor interaction model, targeting small‑molecule treatments for cancer,...
Amprion Diagnostics has commercialized a seed‑amplification assay, SAAmplify‑αSYN, that detects misfolded alpha‑synuclein in cerebrospinal fluid, earning FDA breakthrough‑device status in 2019. The test can identify Parkinson’s, Lewy‑body dementia and up to half of Alzheimer’s cases years before clinical symptoms appear....
UniQure paused dosing in the mid- and high-dose arms of its Phase 1/2a Fabry gene‑therapy trial after two patients experienced grade 3 liver enzyme elevations. The affected cohorts received 4 × 10¹³ and 6 × 10¹³ genome copies per kilogram of AMT‑191, while the low‑dose group...
Roche disclosed phase 3 data showing its oral BTK inhibitor fenebrutinib is non‑inferior to Ocrevus in primary progressive multiple sclerosis (PPMS). The FENtrepid trial demonstrated a 12% relative reduction in disability progression risk over 24 weeks, with a notable 26% improvement...
Ultragenyx reported that its investigational AAV gene therapy UX111 delivers sustained cognitive improvements in Sanfilippo A patients, with follow‑up extending up to 8.5 years. Data from 33 dosed participants—27 receiving the highest dose—showed a 23.3‑point gain on the Bailey‑III scale...
So $LLY not interested in oncology applications of Orna's in vivo Car-T? $ABBV $AZN $BMY $GILD https://t.co/wB3rR5LID8
There you go - $NVO ***FINALLY*** going after $HIMS themselves. DOJ, FDA, $NVO all on board now. Time for $HIMS to get what they deserve.
Novo Nordisk has filed a federal lawsuit against Hims Inc., alleging that the company infringed on patents covering Wegovy, Novo's flagship semaglutide obesity treatment. The complaint seeks damages in the “hundreds of millions” of dollars, reflecting the high commercial stakes...
Hengrui Pharma and Kailera Therapeutics reported Phase 2 results for oral ribupatide, a dual GLP‑1/GIP obesity pill. In a 166‑patient, 26‑week study the drug produced an average 12 % weight loss versus 2 % for placebo, with over half of high‑dose participants shedding...
Novartis has broken ground on a $1.1 billion, 466,000‑sq‑ft biomedical research centre in San Diego, the flagship of a $23 billion U.S. capital investment programme. The campus, slated to open around 2029, will house roughly 1,000 scientists and integrate the company’s West...
MIT Technology Review has launched "Making AI Work," a limited‑run, seven‑week AI mini‑course newsletter that delivers weekly case studies on real‑world AI deployments. The series spans health care, nuclear energy, education, small‑business operations, finance and personal productivity, ending with a...
NIH Director Jay Bhattacharya told the Senate HELP Committee that no scientific study links any vaccine to autism, reaffirming the consensus after senators raised vaccine‑safety concerns. He used the hearing to unveil a modernization agenda that includes centralizing peer review,...
The CDC’s Traveler‑Based Genomic Surveillance (TGS) program has crossed the one‑million‑volunteer threshold, marking a major expansion of upstream pathogen monitoring at U.S. airports. Launched in 2021, TGS combines anonymous nasal swabs from international arrivals with aircraft wastewater sampling, leveraging public‑private...
Canadian startup Kaster Technologies announced a CAD 1.6 million pre‑seed round led by Graphite Ventures, with participation from Hidden Layers Capital and angel investor Louis‑Martin Rousseau. The company offers an AI‑guided software platform that optimizes pharmaceutical production cycles, promising up to...
Cell and gene therapies (CGTs) promise breakthrough treatments but demand highly complex supply chains. The process spans cell collection, manufacturing, temperature‑controlled transport, and delivery, requiring strict regulatory compliance and real‑time data integrity. Developers face challenges such as cold‑chain logistics, stakeholder...
BullFrog AI announced a new scenario‑based decision engine to be released on March 25, adding a strategic layer to its bfPREP™ and bfLEAP® platforms. The engine compares drug programs, indications, and trial designs without forcing single numeric scores, and evaluates portfolio...
Zydus Lifesciences reported a 30% year‑on‑year revenue increase to ₹68.6 bn in Q3 FY2025‑26, driven by strong performance across pharmaceuticals, consumer wellness and medtech. Adjusted net profit rose 9% to ₹11.1 bn, while EBITDA grew 31% to ₹18.2 bn, lifting margins to 26.5%....
Breye Therapeutics presented early-phase data on its oral small‑molecule danegaptide for non‑proliferative diabetic retinopathy (NPDR). In a multi‑centre phase 1b study of 24 patients, the drug was well tolerated and achieved plasma concentrations within the target range. More than half of...
Eli Lilly has deepened its alliance with China‑based Innovent Biologics, signing a new agreement that includes a $350 million upfront payment. The partnership will focus on co‑developing bispecific antibody candidates targeting oncology and immunology indications. Both companies will share development costs, milestone...
Pandorum Technologies, an Indian‑US biotech focused on exosome‑based regenerative therapies, closed an $18 million Series B round led by Protons Corporate. The round, completed in two tranches, values the company at roughly $91 million post‑money, bringing total capital raised to about $43 million. Proceeds...
The U.S. wellness market has been flooded with unapproved "pop" peptides such as BPC‑157, GHK‑Cu and TB‑500, prompting the FDA in 2023 to reclassify most of them as Category 2, effectively banning their compounding. Despite the ban, a gray‑market supply chain—often...
Elevate Now, a doctor‑led clinical weight‑loss platform, secured Rs 18 crore in a seed round headed by Physis Capital, with Inflection Point Ventures and Titan Capital also participating. The Bengaluru startup previously raised $2 million in a pre‑seed round from W Health Ventures,...
Global HealthX, the venture studio of the Global University Foundation, announced it has surpassed $15 million in investments across Indian healthcare and life‑science startups over the past two years. The latest cohort features five companies—TapHealth, Wellytics, Monitra Health, Merry Health and...
2026 regulatory landscape sees the FDA reviving the rare‑pediatric disease priority review voucher (PRV) program, launching the PreCheck manufacturing pilot, and issuing new guidance for multiple myeloma trials and GLP‑1 label warnings. The PRV reinstatement restores a $150 million voucher market,...
Researchers discovered that cerebellar microglia are the sole source of elevated interleukin‑17A (IL‑17A) in a Fragile X mouse model of autism. The microglia‑derived IL‑17A restores Purkinje cell firing rates and normalizes synaptic inhibition, leading to improved social interaction and reduced...
The article argues that current psychiatric diagnostic systems and neuroimaging endophenotypes fail to capture the underlying biological complexity of mental illness. Genetic studies reveal extensive pleiotropy and overlapping risk loci across disorders, while neurotransmitter systems exhibit strong spatial colocalization, creating...
A correction notice was issued for the Molecular Psychiatry article that originally linked gut microbiota to social development in mice. The wrong image was published as Figure 1a and has now been replaced with the correct visual, while Figure 1b and the...
A new review synthesizes recent circuit‑level findings to propose an integrated model for modulating traumatic memories in PTSD. It combines extinction, memory suppression, and reconsolidation mechanisms, emphasizing the amygdala‑prefrontal‑hippocampal network and its neuromodulatory inputs. The authors highlight how this framework...
Within the next 18-24 months every Pharma will have a partner to access the China fast clinical development engine https://t.co/zpLV1XJbvB https://t.co/h5CyXUNO82
GLP‑1 agonists such as Ozempic have surged in popularity for weight loss, but their peptide‑based manufacturing generates massive environmental waste. Current solid‑phase peptide synthesis (SPPS) relies on toxic organic solvents, producing over 123 million pounds of waste annually for semaglutide alone....
ByteDance unveiled Protenix‑v1, an open‑source, AlphaFold3‑style foundation model for all‑atom biomolecular structure prediction covering proteins, nucleic acids and ligands. The 368 million‑parameter system matches AlphaFold3’s training data cutoff, model scale and inference budget, and claims superior performance on curated benchmarks. Protenix...
A recent BMJ article outlines a comprehensive telesurgery architecture comprising robot, telecommunication, and teleconference subsystems. The design employs a dedicated line with a backup path to link the surgeon console and patient cart, while a secondary console resides in the...
